Opus Genetics, Inc. (IRD)
3.83
-0.01
(-0.26%)
USD |
NASDAQ |
Oct 19, 15:49
Opus Genetics Net Income (Quarterly) : -8.098M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.098M |
| March 31, 2026 | -65.54M |
| December 31, 2025 | -16.52M |
| September 30, 2025 | -17.45M |
| June 30, 2025 | -7.42M |
| March 31, 2025 | -8.194M |
| December 31, 2024 | -35.14M |
| September 30, 2024 | -7.526M |
| June 30, 2024 | -7.765M |
| March 31, 2024 | -7.106M |
| December 31, 2023 | -4.795M |
| September 30, 2023 | 5.561M |
| June 30, 2023 | -4.961M |
| March 31, 2023 | -5.791M |
| December 31, 2022 | 33.94M |
| September 30, 2022 | -4.531M |
| June 30, 2022 | -4.927M |
| March 31, 2022 | -6.595M |
| December 31, 2021 | -6.313M |
| September 30, 2021 | -4.23M |
| June 30, 2021 | -7.136M |
| March 31, 2021 | -39.01M |
| September 30, 2020 | -1.248M |
| June 30, 2020 | -2.511M |
| March 31, 2020 | -3.088M |
| Date | Value |
|---|---|
| December 31, 2019 | -1.869M |
| September 30, 2019 | -1.959M |
| June 30, 2019 | -2.464M |
| March 31, 2019 | -2.343M |
| December 31, 2018 | -3.117M |
| September 30, 2018 | -5.339M |
| June 30, 2018 | -3.838M |
| March 31, 2018 | -2.075M |
| December 31, 2017 | -3.592M |
| September 30, 2017 | -1.038M |
| June 30, 2017 | 0.9471M |
| March 31, 2017 | -21.61M |
| December 31, 2016 | -0.5255M |
| September 30, 2016 | -2.867M |
| June 30, 2016 | -1.766M |
| March 31, 2016 | -4.149M |
| December 31, 2015 | -2.852M |
| September 30, 2015 | -4.026M |
| June 30, 2015 | -3.234M |
| March 31, 2015 | -4.272M |
| December 31, 2014 | -2.210M |
| September 30, 2014 | -1.905M |
| June 30, 2014 | 0.1945M |
| March 31, 2014 | -14.60M |
| December 31, 2013 | -2.720M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Rezolute, Inc. | -20.49M |
| Faeth Therapeutics, Inc. | -16.01M |
| Nuvectis Pharma, Inc. | -7.02M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.755M |
| Total Expenses (Quarterly) | 8.853M |
| EPS Diluted (Quarterly) | -0.139 |
| Enterprise Value | 264.76M |
| Gross Profit Margin (Quarterly) | 98.15% |
| Profit Margin (Quarterly) | -1.07K% |
| Earnings Yield | -35.95% |
| Normalized Earnings Yield | -22.36 |